Hot Features
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation ... Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.011 | -6.11111111111 | 0.18 | 0.1975 | 0.1645 | 3283273 | 0.1855402 | CS |
| 4 | -0.0418 | -19.8292220114 | 0.2108 | 0.22 | 0.16 | 2584295 | 0.18749126 | CS |
| 12 | -0.191 | -53.0555555556 | 0.36 | 0.36 | 0.16 | 4544515 | 0.22137008 | CS |
| 26 | -1.251 | -88.0985915493 | 1.42 | 1.55 | 0.16 | 2211678 | 0.23919838 | CS |
| 52 | -0.181 | -51.7142857143 | 0.35 | 7.25 | 0.16 | 5403148 | 0.6192598 | CS |
| 156 | -4.341 | -96.2527716186 | 4.51 | 7.25 | 0.1414 | 2525142 | 0.71453095 | CS |
| 260 | -4.341 | -96.2527716186 | 4.51 | 7.25 | 0.1414 | 2525142 | 0.71453095 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.